Sanofi India Limited (SANOFI.NS)
INR 6082.6
(-0.65%)
INR 6082.6
(-0.65%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 6.63 Billion INR | 62.7% |
| 2022 | 4.08 Billion INR | 3.98% |
| 2021 | 3.92 Billion INR | 6.63% |
| 2020 | 3.68 Billion INR | -22.02% |
| 2019 | 4.71 Billion INR | -4.01% |
| 2018 | 4.91 Billion INR | 15.07% |
| 2017 | 4.27 Billion INR | -14.35% |
| 2016 | 4.98 Billion INR | 2.98% |
| 2015 | 4.84 Billion INR | 0.66% |
| 2014 | 4.81 Billion INR | 39.64% |
| 2013 | 3.44 Billion INR | 24.6% |
| 2012 | 2.76 Billion INR | 8.76% |
| 2011 | 2.54 Billion INR | 5.37% |
| 2010 | 2.41 Billion INR | 4.41% |
| 2009 | 2.31 Billion INR | 33.95% |
| 2008 | 1.72 Billion INR | -4.56% |
| 2007 | 1.8 Billion INR | 13.85% |
| 2006 | 1.58 Billion INR | 16.48% |
| 2005 | 1.36 Billion INR | 34.13% |
| 2004 | 1.01 Billion INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 3.56 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 4.11 Billion INR | 0.0% |
| 2023 FY | 6.63 Billion INR | 62.7% |
| 2023 Q4 | 6.63 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 4.08 Billion INR | 0.0% |
| 2022 FY | 4.08 Billion INR | 3.98% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 3.95 Billion INR | 0.0% |
| 2021 Q4 | 3.92 Billion INR | 0.0% |
| 2021 Q2 | 3.63 Billion INR | 0.0% |
| 2021 FY | 3.92 Billion INR | 6.63% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q4 | 3.68 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 3.42 Billion INR | 0.0% |
| 2020 FY | 3.68 Billion INR | -22.02% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q2 | 4.83 Billion INR | 0.0% |
| 2019 FY | 4.71 Billion INR | -4.01% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 4.71 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 FY | 4.91 Billion INR | 15.07% |
| 2018 Q2 | 4.37 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 4.91 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q4 | 4.27 Billion INR | 0.0% |
| 2017 FY | 4.27 Billion INR | -14.35% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 4.25 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q4 | 4.98 Billion INR | 0.0% |
| 2016 FY | 4.98 Billion INR | 2.98% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 4.49 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 4.84 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 5.02 Billion INR | 0.0% |
| 2015 FY | 4.84 Billion INR | 0.66% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 3.34 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 4.81 Billion INR | 39.64% |
| 2014 Q4 | 4.81 Billion INR | 0.0% |
| 2013 Q2 | 3.53 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 3.44 Billion INR | 24.6% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 3.44 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 FY | 2.76 Billion INR | 8.76% |
| 2012 Q4 | 2.76 Billion INR | 0.0% |
| 2012 Q2 | 2.99 Billion INR | 0.0% |
| 2011 FY | 2.54 Billion INR | 5.37% |
| 2011 Q4 | 2.54 Billion INR | 0.0% |
| 2010 FY | 2.41 Billion INR | 4.41% |
| 2009 FY | 2.31 Billion INR | 33.95% |
| 2008 FY | 1.72 Billion INR | -4.56% |
| 2007 FY | 1.8 Billion INR | 13.85% |
| 2006 FY | 1.58 Billion INR | 16.48% |
| 2005 FY | 1.36 Billion INR | 34.13% |
| 2004 FY | 1.01 Billion INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Abbott India Limited | 6.19 Billion INR | -7.137% |
| Cipla Limited | 52.37 Billion INR | 87.327% |
| Gland Pharma Limited | 16.55 Billion INR | 59.897% |
| GlaxoSmithKline Pharmaceuticals Limited | 5.33 Billion INR | -24.328% |
| Kopran Limited | 1.38 Billion INR | -379.325% |
| Marksans Pharma Limited | 6.17 Billion INR | -7.421% |
| NGL Fine-Chem Limited | 433.03 Million INR | -1432.905% |
| Pfizer Limited | 4.33 Billion INR | -53.059% |
| SMS Pharmaceuticals Limited | 2.33 Billion INR | -184.042% |
| TTK Healthcare Limited | 969.89 Million INR | -584.402% |